GenapSys™ has developed a novel electrical-based platform capable of accurately detecting single-base incorporations. The semiconductor chip-based detection modality allows the system to be compact, scalable, and affordable. The GenapSys platform has been successfully demonstrated in a range of applications that include targeted sequencing to elucidate both germline and somatic mutations, as well as sequencing a range of small genomes.
Update your expectations about how accurate, scalable and affordable DNA sequencing can be. The GenapSys Sequencer is based on our novel and robust sequencing technology. The GenapSys Sequencing Prep System replaces the manual clonal amplification step in the GenapSys Sequencer workflow with a load-and-go process that automates template preparation and enrichment in one device.
GenapSys™ has developed a novel, scalable, low cost NGS platform that is capable of generating accurate sequence information needed for a range of applications, including Variant Calling, Oncology Research, Small Genome Sequencing and SARS-CoV-2 Sequencing.
ASK US ANYTHING
Gulf Scientific Corporation
PO Box 17010
Street N500 Jebel Ali Freezone (JAFZA 4)
Dubai, United Arab Emirates
08:00 – 17:00
Tel: +971 4 881 5270
Fax: +971 4 881 6778
GenapSys™ Sequencing Platform
The GenapSys™ Sequencer is based on novel and robust sequencing technology. GenapSys’ proprietary NGS technology with proven Sequencing-by-Synthesis chemistry employs electrical-based detection of single nucleotide incorporations. With CMOS-based detectors (Complementary Metal Oxide Semiconductor), simple fluidics, and no moving parts, the GenapSys Sequencer is compact, robust, easy to use, and inexpensive.
GenapSys™ Sequencing Prep System
The GenapSys™ Sequencing Prep System replaces the manual clonal amplification step in the GenapSys Sequencer workflow with a load-and-go process that automates template preparation and enrichment in one device. This small-footprint instrument uses cartridge-based reagents, and employs magnetic bead technology to isolate template-positive particles that can be subsequently loaded onto GenapSys sequencing chips.
The GenapSys NGS technology is based on the detection of electrical impedance changes resulting from single base incorporations during sequencing-by-synthesis. The core of the technology is a CMOS-based electronic chip that enables scalability and low instrument and consumable costs. Chips with low, medium, and high sensor throughputs can be run on the same GenapSys instrument, offering the user flexibility in NGS assay design and sample multiplexing.
NGS technologies have made rapid strides in the throughput and accuracy of DNA sequencing in recent years. These advances have revolutionized biomedical and clinical research, especially in oncology. NGS cancer assays are used for determining cancer predisposition and early detection; identifying key tumor mutations; monitoring treatment response; and making progress towards personalized therapies. The GenapSys NGS platform is an ideal solution for a diverse range of oncology research applications.
Small Genome Sequencing
Advances in NGS have revolutionized the way biologists study organisms with small genomes (< 10 Mb), including viruses, bacteria, archaea, and other microorganisms. Applications of small genome sequencing include genome assembly, pathogen identification, comparative genomics, and analysis of biosynthetic pathways, just to name a few. The GenapSys Sequencing Platform that generates more than 1.2 Gb of highly accurate DNA sequence data per run is the ideal tool for addressing such applications.
The GenapSys™ Sequencer employs a novel electrical detection method that is capable of generating highly accurate DNA sequence information. GenapSys has demonstrated high accuracy sequencing of the full SARS-CoV-2 genome using both hybrid capture panels and multiplex amplicon PCR panels.